REGN — Regeneron Pharmaceuticals Share Price
Last trade - 00:00- $98.44bn
- $90.29bn
- $13.12bn
- 94
- 32
- 88
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.53 | ||
| PEG Ratio (f) | 1.31 | ||
| EPS Growth (f) | 17.49% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.79 | ||
| Price to Tang. Book | 3.95 | ||
| Price to Free Cashflow | 26.84 | ||
| Price to Sales | 7.5 | ||
| EV to EBITDA | 20.21 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.65% | ||
| Return on Equity | 16.26% | ||
| Operating Margin | 30.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7,863.4 | 8,497.1 | 16,071.7 | 12,172.9 | 13,117.2 | 13,948.41 | 14,956.23 | 14.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -10.81 | +65.32 | +135.8 | -43.77 | -10.04 | +24.21 | +5.11 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.
Directors
- P. Roy Vagelos CHM (91)
- Leonard Schleifer PRE (68)
- George Yancopoulos CPR (61)
- Robert Landry CFO (57)
- Joseph LaRosa EVP (62)
- Daniel Van Plew EVP (48)
- Marion McCourt EVP (61)
- Andrew Murphy EVP (63)
- Neil Stahl EVP (64)
- Christopher Fenimore SVP (50)
- Bonnie Bassler IND (58)
- Michael Brown IND (80)
- N. Anthony Coles IND (61)
- Joseph Goldstein IND (80)
- Christine Poon IND (68)
- Arthur Ryan IND (78)
- George Sing IND (71)
- Marc Tessier-Lavigne IND (61)
- Huda Zoghbi IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 11th, 1988
- Public Since
- April 2nd, 1991
- No. of Shareholders
- 167
- No. of Employees
- 13,450
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 109,761,896
- Address
- 777 Old Saw Mill River Road, TARRYTOWN, 10591
- Web
- https://www.regeneron.com/
- Phone
- +1 7813705000
- Auditors
- PricewaterhouseCoopers LLP
Latest News for REGN
Upcoming Events for REGN
Q1 2024 Regeneron Pharmaceuticals Inc Earnings Call
Q1 2024 Regeneron Pharmaceuticals Inc Earnings Release
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting
Regeneron Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Regeneron Pharmaceuticals Inc Earnings Release
Similar to REGN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:18 UTC, shares in Regeneron Pharmaceuticals are trading at $896.82. This share price information is delayed by 15 minutes.
Shares in Regeneron Pharmaceuticals last closed at $896.82 and the price had moved by +12.37% over the past 365 days. In terms of relative price strength the Regeneron Pharmaceuticals share price has underperformed the S&P500 Index by -6.49% over the past year.
The overall consensus recommendation for Regeneron Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Regeneron Pharmaceuticals does not currently pay a dividend.
Regeneron Pharmaceuticals does not currently pay a dividend.
Regeneron Pharmaceuticals does not currently pay a dividend.
To buy shares in Regeneron Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $896.82, shares in Regeneron Pharmaceuticals had a market capitalisation of $98.44bn.
Here are the trading details for Regeneron Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: REGN
Based on an overall assessment of its quality, value and momentum Regeneron Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Regeneron Pharmaceuticals is $1,048.72. That is 16.94% above the last closing price of $896.82.
Analysts covering Regeneron Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $45.22 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regeneron Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -5.83%.
As of the last closing price of $896.82, shares in Regeneron Pharmaceuticals were trading +4.38% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Regeneron Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 19.53. The shares last closed at $896.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Regeneron Pharmaceuticals' management team is headed by:
- P. Roy Vagelos - CHM
- Leonard Schleifer - PRE
- George Yancopoulos - CPR
- Robert Landry - CFO
- Joseph LaRosa - EVP
- Daniel Van Plew - EVP
- Marion McCourt - EVP
- Andrew Murphy - EVP
- Neil Stahl - EVP
- Christopher Fenimore - SVP
- Bonnie Bassler - IND
- Michael Brown - IND
- N. Anthony Coles - IND
- Joseph Goldstein - IND
- Christine Poon - IND
- Arthur Ryan - IND
- George Sing - IND
- Marc Tessier-Lavigne - IND
- Huda Zoghbi - IND